Ding Ai1, Hongfeng Jiang, Marit Westerterp, Andrew J Murphy, Mi Wang, Anjali Ganda, Sandra Abramowicz, Carrie Welch, Felicidad Almazan, Yi Zhu, Yury I Miller, Alan R Tall. 1. From the Division of Molecular Medicine, Department of Medicine, Columbia University, New York, NY (D.A., H.J., M. Westerterp, A.J.M., M. Wang, A.G., S.A., C.W., A.R.T.); Department of Physiology, Tianjin Medical University, Tianjin, China (D.A., Y.Z.); Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (M. Westerterp); and Department of Medicine, University of California at San Diego, CA (F.A., Y.I.M.).
Abstract
RATIONALE: The mammalian target of rapamycin complex 1 inhibitor, rapamycin, has been shown to decrease atherosclerosis, even while increasing plasma low-density lipoprotein levels. This suggests an antiatherogenic effect possibly mediated by the modulation of inflammatory responses in atherosclerotic plaques. OBJECTIVE: Our aim was to assess the role of macrophage mammalian target of rapamycin complex 1 in atherogenesis. METHODS AND RESULTS: We transplanted bone marrow from mice in which a key mammalian target of rapamycin complex 1 adaptor, regulatory-associated protein of mTOR, was deleted in macrophages by Cre/loxP recombination (Mac-Rap(KO) mice) into Ldlr(-/-) mice and then fed them the Western-type diet. Atherosclerotic lesions from Mac-Rap(KO) mice showed decreased infiltration of macrophages, lesion size, and chemokine gene expression compared with control mice. Treatment of macrophages with minimally modified low-density lipoprotein resulted in increased levels of chemokine mRNAs and signal transducer and activator of transcription (STAT) 3 phosphorylation; these effects were reduced in Mac-Rap(KO) macrophages. Although wild-type and Mac-Rap(KO) macrophages showed similar STAT3 phosphorylation on Tyr705, Mac-Rap(KO) macrophages showed decreased STAT3Ser727 phosphorylation in response to minimally modified low-density lipoprotein treatment and decreased Ccl2 promoter binding of STAT3. CONCLUSIONS: The results demonstrate cross-talk between nutritionally induced mammalian target of rapamycin complex 1 signaling and minimally modified low-density lipoprotein-mediated inflammatory signaling via combinatorial phosphorylation of STAT3 in macrophages, leading to increased STAT3 activity on the chemokine (C-C motif) ligand 2 (monocyte chemoattractant protein 1) promoter with proatherogenic consequences.
RATIONALE: The mammalian target of rapamycin complex 1 inhibitor, rapamycin, has been shown to decrease atherosclerosis, even while increasing plasma low-density lipoprotein levels. This suggests an antiatherogenic effect possibly mediated by the modulation of inflammatory responses in atherosclerotic plaques. OBJECTIVE: Our aim was to assess the role of macrophage mammalian target of rapamycin complex 1 in atherogenesis. METHODS AND RESULTS: We transplanted bone marrow from mice in which a key mammalian target of rapamycin complex 1 adaptor, regulatory-associated protein of mTOR, was deleted in macrophages by Cre/loxP recombination (Mac-Rap(KO) mice) into Ldlr(-/-) mice and then fed them the Western-type diet. Atherosclerotic lesions from Mac-Rap(KO) mice showed decreased infiltration of macrophages, lesion size, and chemokine gene expression compared with control mice. Treatment of macrophages with minimally modified low-density lipoprotein resulted in increased levels of chemokine mRNAs and signal transducer and activator of transcription (STAT) 3 phosphorylation; these effects were reduced in Mac-Rap(KO) macrophages. Although wild-type and Mac-Rap(KO) macrophages showed similar STAT3 phosphorylation on Tyr705, Mac-Rap(KO) macrophages showed decreased STAT3Ser727 phosphorylation in response to minimally modified low-density lipoprotein treatment and decreased Ccl2 promoter binding of STAT3. CONCLUSIONS: The results demonstrate cross-talk between nutritionally induced mammalian target of rapamycin complex 1 signaling and minimally modified low-density lipoprotein-mediated inflammatory signaling via combinatorial phosphorylation of STAT3 in macrophages, leading to increased STAT3 activity on the chemokine (C-C motif) ligand 2 (monocyte chemoattractant protein 1) promoter with proatherogenic consequences.
Entities:
Keywords:
atherosclerosis; macrophages; mammalian target of rapamycin complex 1
Authors: David A Guertin; Deanna M Stevens; Carson C Thoreen; Aurora A Burds; Nada Y Kalaany; Jason Moffat; Michael Brown; Kevin J Fitzgerald; David M Sabatini Journal: Dev Cell Date: 2006-12 Impact factor: 12.270
Authors: Yun Soo Bae; Jee Hyun Lee; Soo Ho Choi; Sunah Kim; Felicidad Almazan; Joseph L Witztum; Yury I Miller Journal: Circ Res Date: 2008-12-18 Impact factor: 17.367
Authors: Thomas Weichhart; Giuseppina Costantino; Marko Poglitsch; Margit Rosner; Maximilian Zeyda; Karl M Stuhlmeier; Thomas Kolbe; Thomas M Stulnig; Walter H Hörl; Markus Hengstschläger; Mathias Müller; Marcus D Säemann Journal: Immunity Date: 2008-10-09 Impact factor: 31.745
Authors: Soo-Ho Choi; Richard Harkewicz; Jee Hyun Lee; Agnès Boullier; Felicidad Almazan; Andrew C Li; Joseph L Witztum; Yun Soo Bae; Yury I Miller Journal: Circ Res Date: 2009-05-21 Impact factor: 17.367
Authors: Ashley Orillion; Nur P Damayanti; Li Shen; Remi Adelaiye-Ogala; Hayley Affronti; May Elbanna; Sreenivasulu Chintala; Michael Ciesielski; Luigi Fontana; Chinghai Kao; Bennett D Elzey; Timothy L Ratliff; David E Nelson; Dominic Smiraglia; Scott I Abrams; Roberto Pili Journal: Clin Cancer Res Date: 2018-09-06 Impact factor: 12.531
Authors: Min-Hee Oh; Samuel L Collins; Im-Hong Sun; Ada J Tam; Chirag H Patel; Matthew L Arwood; Yee Chan-Li; Jonathan D Powell; Maureen R Horton Journal: Cell Rep Date: 2017-09-05 Impact factor: 9.423
Authors: Shayla S Shojaat; Samuel Engman; Jason Hofferber; Faithe Keomanivong; Eric M Wauson Journal: J Physiol Biochem Date: 2020-10-09 Impact factor: 4.158